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Noroviruses represent the most important cause of acute gastroenteritis worldwide; however, currently no li-
censed vaccine exists. Widespread vaccination that minimizes overall norovirus disease burden would benefit
the entire population, but targeted vaccination of specific populations such as healthcare workers may further
mitigate the risk of severe disease and death in vulnerable populations. While a few obstacles hinder the rapid
development of efficacious vaccines, human trials for virus-like particle (VLP)-based vaccines show promise in
both immune response and protection studies, with availability of vaccines being targeted over the next 5–10
years. Ongoing work including identification of important norovirus capsid antigenic sites, development of im-
proved model systems, and continued studies in humans will allow improvement of future vaccines. In the
meantime, a better understanding of norovirus disease course and transmission patterns can aid healthcare
workers as they take steps to protect high-risk populations such as the elderly and immunocompromised indi-
viduals from chronic and severe disease.
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Noroviruses are the primary cause of acute gastroenteritis
in the United States and worldwide, and infection is typ-
ically characterized by vomiting and/or diarrhea for 24–
48 hours. Each year in the United States, noroviruses in-
fect an estimated 21 million people and result in about
70 000 hospitalizations and 800 deaths [1]. Norovirus in-
fections are most prevalent in the fall and winter months
and can spread easily in areas where people are in close
proximity, including day-care centers, schools, cruise
ships, and in healthcare settings. In healthcare settings,
noroviruses can cause death or severe disease outcomes
in elderly and immunocompromised individuals and
can result in chronic infection in transplant patients
and those with immune disorders [2].There are currently
no licensed vaccines for noroviruses, although several
candidates are under development, and projections indi-
cate that an efficacious vaccine could have both economic
and clinical benefits [3].
Noroviruses are nonenveloped, single-stranded, pos-
itive sense RNAviruses in the Caliciviridae family. Nor-
oviruses are divided into 5 genogroups, and each is
further subdivided into numerous genotypes. Gen-
ogroups I and II (GI and GII) are responsible for the
majority of human disease and are comprised of at
least 9 and 22 distinct genotypes, respectively [4].
While fluctuations in norovirus epidemiology occur by
year and geographic location, GI strains generally cause
approximately 10% of human disease, while the GII
strains are responsible for the remaining approximately
90% [5]. A single genotype, GII.4, is responsible for
more than 70% of all human outbreaks since the mid-
1990s [5]. Consequently, in terms of medical relevance,
GII.4 noroviruses are key strains targeted by vaccines.
Histoblood group antigens (HBGAs) serve as bind-
ing ligands and putative receptors for human norovirus
docking and entry, and the presence of particular
HBGAs in an individual is under specific genetic con-
trol. Upon infection, noroviruses replicate in cells in the
small intestines and virus is shed in feces. Noroviru-
ses infect via the oral route, transmitted through con-
tact with fecal matter or aerosolized vomitus from
infected people as well as contaminated surfaces, food,
or water. Noroviruses are environmentally stable and
have an infectious dose of between 18 and 2800 parti-
cles [6, 7], making it difficult to prevent their spread, as
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even small amounts of viral contamination can seed new
infections.
FACTORS COMPLICATING VACCINE DESIGN
Vaccine development for noroviruses is complex (Figure 1).
Noroviruses do not replicate in tissue culture and, until recently,
there was no small animal model for human norovirus infection
[8]. Because of the lack of a validated tissue culture model, virus
neutralization cannot be directly measured after infection or
vaccination. Instead, the virus-like particle (VLP)-HBGA block-
ade assay has been used as a surrogate to evaluate the potential
neutralization response of both monoclonal antibodies and sera
[9], and blockade titers in this assay correlate with human pro-
tection [10]. Both chimpanzee and gnotobiotic pig models have
been developed to evaluate vaccine efficacy [11, 12]. However,
studies have been halted in chimpanzees due to ethical restric-
tions on the use of these nonhuman primates. To date, results
from only 1 vaccine efficacy study in gnotobiotic pigs have
been published [11]. Because of limitations in growing virus
and testing different vaccines and therapeutics outside of
humans, the factors that modulate vaccine efficacy remain
poorly understood.
Noroviruses are highly heterogeneous viruses, and major an-
tigenic differences exist between GI and GII noroviruses. With-
in the GI genogroup, antibodies from different genotypes share
5%–10% cross-reactivity, while cross-reactivity between GI and
GII genotypes is <5% [13]. Furthermore, no shared neutraliza-
tion epitopes have been identified between the 2 genogroups,
suggesting that a multivalent GI + GII vaccine platform is need-
ed to protect against infection with both GI and GII viruses. Al-
though poorly characterized, there appear to be some complex
cross-blockade relationships that exist within and between GI
and GII genogroups, respectively, meaning that inclusion of
strategically chosen representative GI and GII strains may
yield a broadly protective vaccine [13].While most noroviruses
do not undergo substantial intragenotype antigenic variation,
GII.4 noroviruses are a notable exception. The GII.4 genotype
varies considerably over time by both mutation and RNA re-
combination processes, suggesting that a successful vaccine
will likely need to be reformulated periodically with contempo-
rary isolates. Antigenic variation within the GII.4 noroviruses is
linked to genetic changes in potential neutralization sites on the
major capsid protein P2 domain [14–17], providing discrete
areas to target with vaccines. Every 2–4 years the predominant
circulating GII.4 strain is replaced by a new, antigenically dis-
tinct emergent strain that is able to overcome human herd im-
munity [18–20]. GII.3 noroviruses also demonstrate antigenic
changes over time; however, their evolutionary mechanisms dif-
fer from those of GII.4 noroviruses and are not as well studied
[21]. In contrast, GI.1 and GII.2 isolates have demonstrated little
if any antigenic variation over the past 30 years [22]. It is un-
clear whether these genogroup-specific patterns of evolution
are stable or whether all strains have the potential to evolve
by epochal evolution like the GII.4 genotype under the appro-
priate environmental conditions, leading to epidemic strain re-
placement over time, as seen with influenza A viruses.
The duration of protective immunity after human norovirus
infection is complex. Early human challenge studies suggested
that protection lasts only approximately 6 months to 2 years
[23], leading to concerns regarding the feasibility of developing
a successful norovirus vaccine. Others have postulated that
some individuals develop long-lived immunity [14]. Although
still under study, more recent work that is based on modeling
of epidemiological data estimates that protective immunity
after natural norovirus infection may persist for between 4
and 8 years [23], suggesting that norovirus vaccines could effec-
tively reduce the overall severity and global disease burden. An-
other complicating factor is the potential for previous exposure
to norovirus strains to impact the immune response to newly
encountered strains. Preexposure history may complicate vac-
cine performance, as most individuals are exposed to multiple
Figure 1. Factors that complicate norovirus vaccine design. Vaccine de-
velopment for noroviruses is hampered by several factors including the lim-
ited number of challenge and vaccine efficacy studies done in humans, the
absence of a cell culture system and limited animal models for testing vac-
cines, the limited and conflicting data on how long protective immunity
lasts after infection or vaccination in humans, differing evolutionary pat-
terns and antigenic profiles between genogroups and among genotypes
within genogroups, antigenic variation within GII.4 noroviruses and possi-
bly within other genotypes, and the unknown effects of exposures to mul-
tiple norovirus genotypes and strains during a lifetime on the immune
response to newly encountered strains.
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GI and GII norovirus infections over their lifetime, resulting in
complex patterns of cross-immunity and potentially short- or
long-term cross-protection. Although controversial, repeated
exposures may lead to deceptive imprinting, where the immune
response is increasingly directed at nonneutralizing epitopes, as
has been described for other viruses such as human immuno-
deficiency virus (HIV) and influenza [24]. However, this has
not yet been thoroughly investigated after norovirus infections
or vaccination.
Available results from 2 human vaccine efficacy studies are
encouraging; however, our ability to compare and contrast vac-
cine platform performance is currently limited. The high het-
erogeneity of antigenic profiles between genogroups, between
some genotypes, and within the GII.4 genogroup suggest that
broad vaccine-induced protection against multiple norovirus
groups may be difficult but possible, especially if multivalent
vaccines are used to broaden reactivity and blockade responses.
One study found that immunization of mice against multiple
strains broadens the serum blockade response against both ho-
motypic VLPs and VLPs that represent strains not included in
the vaccine formulation [13]. Likewise, researchers examining
the strain cross-reactivity induced by a bivalent GI.1/GII.4 con-
sensus VLP vaccine in rabbits found that heterotypic strain
cross-reactivity was induced [25]. Together, these studies sug-
gest that a multivalent vaccine approach may induce broad pro-
tection in humans; however, this remains to be evaluated in
human trials.
VACCINE STRATEGIES FOR NOROVIRUSES
The first human clinical efficacy trials evaluated norovirus VLP
vaccines. The multivalent human papillomavirus (HPV) vac-
cines Gardasil and Cervarix are VLP-based vaccines that have
been shown to be highly effective at preventing HPV infections
and precancerous lesions for strains included in the vaccine
[26]. Successes of HPV multivalent VLP vaccines provide a
template strategy for use with other viruses, including norovi-
ruses. Takeda Pharmaceutical Company conducted human tri-
als on a monovalent GI.1 VLP-based vaccine that is delivered
intranasally [27–29]. All participants in phase 1 studies were
found to have significant increases in immunoglobulin (Ig) A
and/or IgG memory B-cell responses at the highest vaccine
dose of 100 μg VLP [28]. In a follow-up human challenge
study, participants were given 2 vaccine doses, 3 weeks apart,
and then challenged with 10× ID50 (the dose required to infect
∼50% of participants) Norwalk virus 3 weeks after the second
vaccine dose [29]. Results from this study showed that both gas-
trointestinal disease and Norwalk infection were reduced in the
vaccinated group compared with the control group by 47% and
26%, respectively [29]. Long-term efficacy trials are currently
underway to evaluate duration of protection for this vaccine.
Takeda Pharmaceutical is also developing a bivalent VLP-
based norovirus vaccine that contains both GI.1 Norwalk and
GII.4 components. The GI.1 component is identical to that
used in the monovalent vaccine trial, and the GII.4 component
is based on a consensus sequence from 3 GII.4 outbreak strains
that first circulated widely in 2002 and 2006 [25]. Phase 1 and 2
human clinical trials with the intramuscular bivalent vaccine
formulation were conducted with a group of 98 healthy partic-
ipants aged 18–50 years and was found to be well tolerated [30].
While Takeda Pharmaceutical reported that the primary com-
posite study endpoint was not met, study results were encour-
aging. No severe vomiting and diarrhea were reported in any of
the vaccinated recipients, compared with 4 individuals who ex-
hibited these symptoms in the placebo group after challenge
[30]. Furthermore, results demonstrated a 52% reduction of
vomiting and diarrhea of any severity in the vaccinated group
compared with the control group after challenge [30]. Contin-
ued clinical trials and long-term efficacy studies are currently
planned and underway to further evaluate this vaccine.
Other vaccine approaches under development include addi-
tional multivalent VLP-based vaccines [31], multivalent alpha-
virus replicon particles (VRPs) that allow formation of norovirus
VLPs [13], delivery of VLPs by edible vaccine [32], P particle–
based vaccines [33], and polyvalent norovirus P domain–GST
complexes [34]. These platforms have not been evaluated in
human efficacy studies, but mouse and human immune induc-
tion studies provide clues as to which platforms may be most
promising for further development and eventual human chal-
lenge trials. Notably, while live-attenuated vaccines have been
successful for rotavirus and influenza, the lack of a culture sys-
tem for human norovirus makes development of a live-attenu-
ated norovirus vaccine untenable and dependent on future basic
scientific discoveries.
Work with a multivalent VRP vaccine demonstrated that
VRPs are an efficient way to deliver norovirus VLPs; this vac-
cine was able to induce mucosal and cellular immune respons-
es, including more broadly blocking immune responses to the
heterologous strain VLPs compared with single-strain VRPs
in mice [13]. These results were corroborated by work with
a trivalent norovirus/rotavirus combination vaccine that con-
tained both GII.4 and GI.3 norovirus representatives and ro-
tavirus VP6 that was able to broadly block VLPs representing
both homotypic (GII.4 VA387 and GI.3) and heterotypic
(GII.4 NO and GI.1) norovirus strains [31]. Though in their
infancy, edible norovirus vaccines may have potential. A
study with 24 participants who either ingested transgenic po-
tatoes expressing norovirus VLPs or wild-type potatoes dem-
onstrated that 95% and 20% of those who ate the transgenic
potatoes developed significant increases is IgA-specific anti-
body-secreting cells and strain-specific serum IgG responses,
respectively [32].
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P particles, which are 24-mer particles comprised of the P
domain of the norovirus capsid, have also been evaluated for
their ability to induce immune responses in mice. While P par-
ticles were found to stimulate both cellular and humoral im-
mune responses [33], 1 study demonstrated that VLPs, not P
particles, induced cross-reactive B- and T-cell responses and
primed T cells for production of interferon-γ [35]. Another
study found that some P particles do not present surface block-
ade epitopes as efficiently as VLPs. Taken together, these data
suggest that VLPs may be a more promising vaccine strategy
than P particles [36].
Polyvalent complexes address issues of low immunogenicity
associated with smaller antigens such as P particles by creating a
platform that results in large complexes that induce immune in-
duction more efficiently than individual smaller particles. Fur-
thermore, these complexes are able to incorporate multiple
antigens into 1 particle, potentially allowing for a multivalent
vaccine approach in 1 particle. Sera from mice immunized
with polyvalent complexes that incorporated multiple norovirus
genotypes (GII.4 and GII.9) induced more efficient blocking
ability against both GII.4 P particles and GII.9 VLPs compared
with immunizations with GII.4 and GII.9 P particles, suggesting
their potential utility as a multivalent vaccine platform [34].
Differing approaches are being taken to address GII.4 anti-
genic variation, including incorporation of a VLP that repre-
sents the predominant circulating strain [31] and design of a
GII.4 consensus VLP meant to broaden the GII.4 neutraliza-
tion response [25]. The recent identification of 3 evolving
GII.4 blockade epitopes (designated A, D, and E) that are
linked to antigenic changes in GII.4 strains has provided
more focused vaccine targets [15, 16, 36] (Figure 2). In addition
to modulating antigenicity, epitope D is located in the HBGA
interaction site, and evolution in this epitope impacts specific-
ity of HBGA binding, potentially altering the population sus-
ceptible to infection over time [36]. Importantly, these
discrete epitopes retain their unique antigenic characteristics
when moved between GII.4 strains. Although speculative, a re-
formulation strategy where the GII.4 vaccine component is
changed based on population-wide monitoring of these epi-
topes could be developed. Chimeric VLPs that incorporate epi-
topes from both the emergent strain and circulating strain
could be built to broaden the neutralization response against
multiple GII.4 strains including novel variants. Importantly,
no putative neutralization epitopes have been mapped in
other GI or GII genotypes, making this a basic objective for im-
proving vaccine design in the future.
Figure 2. GII.4 potential neutralization sites. A, A cryo electron microscopy image shows the virion structure for a GII norovirus. Approximate positions are
shown for the capsid protein shell domain (red), the P1 subdomain (yellow/green), and the P2 subdomain (gray). The black circle indicates a single P2 dimer.
B, A single GII.4 norovirus capsid P2 dimer (top view) is shown. Evolving surface-exposed blockade epitopes A (dark blue), D (light blue), and E (purple) are
shown. Histoblood group antigen interaction sites are shown in black. These blockade epitopes represent potential vaccine and drug targets for GII.4
noroviruses.
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VACCINE PROTECTION OF AT-RISK
POPULATIONS
Populations that are at the highest risk for severe disease include
infants and very young children, the elderly, and the immuno-
compromised [37]. More than 60% of norovirus outbreaks
occur in long-term care facilities that serve elderly populations
[5], making protection of this group a top priority. Though a
licensed norovirus vaccine is not yet available, recent work
has estimated the benefits and costs of widespread norovirus
vaccination in terms of clinical and economic outcomes in
the United States. These projections vary based on age group,
vaccine cost, vaccine efficacy rate, and duration of protection
[3]. In patients aged ≥65 years, a vaccine with 50% efficacy
and a 12-month duration of protection would result in preven-
tion of an estimated 214 cases, 22 outpatients visits, and 4
hospitalizations per 10 000 vaccinations; in children aged 0–4
years, an estimated 1133 norovirus cases, 189 outpatient visits,
and 4 hospitalizations would be averted under the same condi-
tions, suggesting that a vaccine would be beneficial to these
high-risk populations [3]. In addition, clinicians who work
with immunocompromised populations, such as transplant pa-
tients, HIV-infected individuals, cancer patients undergoing
chemotherapy, and those with primary immunodeficiencies,
should be aware that chronic norovirus infections can develop
and persist in these patient populations for months to years
[38]. Because the elderly and immunocompromised are notori-
ously poor responders to vaccines [39, 40], vaccination of people
who interact with these populations may be critical to reduction
of the risk of exposure and spread. Healthcare workers and their
family members should be vaccinated to protect against second-
ary spread.
Figure 3. Design of a multivalent norovirus virus-like particle vaccine. A, Large circles represent the 2 major norovirus genogroups that infect humans, GI
and GII. Smaller circles within the larger circles represent the 9 (G1) and 22 (GII) individual genotypes within each genogroup. B, Heterogeneity of GI and GII
viruses necessitates a multivalent vaccine to maximize protective coverage of multiple genotypes. Multivalent vaccines that contain virus-like particles
(VLPs) representing GI.1 and GII.4 components (red circles) cover norovirus genotypes responsible for approximately 80% of outbreaks. However, a mul-
tivalent approach likely broadens the immune response to potentially protect against some heterologous norovirus genotypes (green circles) as well. Het-
erologous genotypes (green) are shown as examples and are not representative of published data. C, Continued work on norovirus VLP vaccines should
consider that there will likely be epidemiological changes over time where relative changes in disease burden by different genotypes occur and strain
replacement occurs every 2–4 years for GII.4 noroviruses. Thus, norovirus vaccines will need to be reformulated over time C.1: in response to changes
in epidemiologically important viruses; and C.2: in response to changing antigenicity of GII.4 noroviruses. Changes in epidemiologically important norovirus
genotypes in C.1 are shown as examples and are not representative of published data.
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Recent work shows that approximately 7.2% of norovirus
outbreaks occur in childcare centers and school environments
[5] and that children are reported to be most efficient at trans-
mitting virus compared with those in other age groups [23]. To-
gether, these data suggest that children and students in day-care
and educational environments may be important populations to
target with a vaccine [5]. However, vaccine outcomes in young
infants and toddlers may be dramatically different from those in
adults due to limited exposure histories, presence of maternal
antibodies, and maturing immune systems in infants. Vaccine
safety and efficacy trials in young children will be critical for il-
luminating these differences.
Other at-risk populations include military personnel, food
handlers, and travelers. Outbreaks can spread rapidly in mili-
tary barracks and vessels [41]; thus, vaccination of military per-
sonnel could reduce disease burden and preserve scheduled
operations and security in this environment. Noroviruses are
the leading cause of foodborne illness, resulting primarily
from contamination by food handlers during food preparation
and processing but also during food production [42]. Vaccina-
tion of food handlers, farm workers, and food-processing facil-
ity workers may prevent outbreaks in restaurants, cruise ships,
cafeterias, at catered events, and from grocery items. Travelers
and travel industry workers are another group that may benefit
from a vaccine, as 2.6% of outbreaks occur in vacation settings
such as on cruise ships [5].
CONCLUSIONS
Predictions suggest that a norovirus vaccine with a 50% efficacy
rate that is protective for 12 months could prevent 1 million to
2.2 million norovirus cases per year in the United States [3], re-
ducing disease severity and burdens in high-risk populations
such as young children and the elderly. Depending on vaccine
cost and duration of protection, a norovirus vaccine will either
save money (up to $2.1 billion) or result in a cost per case avert-
ed similar to other currently available vaccines (<$1500) [3]. As
licensed norovirus vaccines become available, it will be neces-
sary to continue to improve vaccine efficacy. The high antigenic
heterogeneity of the norovirus family, the factors that regulate
short- vs long-term immunity, and the ability of some strains
to evolve quickly in response to human herd immunity repre-
sent considerable challenges for the vaccine industry (Figure 1).
Despite this, epidemiological and immunological data generat-
ed by those who study noroviruses provide a basis on which to
design and reformulate vaccines (Figure 3), including several re-
cent advances that will likely contribute to the improvement of
vaccines. Important antigenic sites have been identified for
GII.4 noroviruses, allowing for more targeted vaccine approach-
es, and recent comparative studies on multiple vaccine plat-
forms are beginning to elucidate which approaches generate
the most robust immune responses. In addition, ongoing and
potential future vaccine efficacy studies using the new mouse
model and gnotobiotic pigs will inform development and im-
provements to human vaccines. Furthermore, continued work
using available human challenge models for GI.1, GII.2, and
GII.4 strains will provide numerous opportunities to test vac-
cine and immune outcomes in immunocompetent and at-risk
populations, a strength for improving vaccine design over the
next decade.
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